Multiple sclerosis Damage can also disrupt the blood-brain barrier and related vascular barriers, while later remyelination is one proposed component of neural repair.
Parkinson’s disease
Alzheimer’s disease
ALS
Peripheral neuropathy
Plain-language overview
Neurologic diseases are not one category biologically. A stroke, traumatic injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, ALS, and peripheral neuropathy damage the nervous system in very different ways.
Research involving mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) has explored anti-inflammatory, protective, vascular, and repair-related effects. These proposed mechanisms are scientifically interesting, but they do not prove that damaged neurons are replaced or that meaningful neurologic function is restored.
MSC and EV treatments for these neurologic conditions remain investigational. Established emergency treatment, disease-modifying therapy, symptomatic treatment, and rehabilitation should not be displaced by claims based mainly on biological plausibility.
Ischemic stroke
Ischemic stroke occurs when blood flow to part of the brain is blocked. Brain injury develops rapidly, which is why emergency evaluation and proven reperfusion treatments are time-sensitive.
MSC and EV research has mainly examined later repair processes such as neuroprotection, neuroinflammation, neuroplasticity, vascular signaling, and support of the neurovascular unit.
These experimental approaches are not substitutes for thrombolysis or mechanical thrombectomy in eligible patients. Human studies have used different products, doses, routes, and treatment windows, and routine clinical benefit has not been established.
Figure 1 placeholder — Ischemic stroke
Hemorrhagic stroke
Hemorrhagic stroke occurs when bleeding damages the brain or surrounding structures. The injury can involve the blood itself, pressure, swelling, inflammation, and secondary tissue damage.
This is biologically different from an ischemic stroke, so cell-therapy findings from blocked-artery stroke cannot simply be transferred to brain hemorrhage.
MSC and EV studies remain largely preclinical or early clinical. Acute treatment is driven by the type and location of bleeding, blood pressure, coagulation, pressure effects, and possible neurosurgical needs.
Figure 2 placeholder — Hemorrhagic stroke
Traumatic brain injury
Traumatic brain injury can range from a focal brain contusion to diffuse axonal injury. Secondary injury may involve excitotoxicity, inflammation, vascular problems, metabolic stress, and swelling.
MSC and EV research has explored whether biological signaling might reduce secondary injury or support later recovery.
Interpretation is difficult because injury severity, age, treatment timing, rehabilitation, and spontaneous recovery differ greatly among patients. Early studies do not prove that administered cells replace damaged neurons.
Figure 3 placeholder — Traumatic brain injury
Spinal-cord injury
Spinal-cord injury begins with mechanical damage and can be followed by inflammation, ischemia, demyelination, axonal injury, and formation of a glial scar.
Investigational MSC or EV approaches mainly aim to influence the environment around injured tissue through signaling and immunomodulation. This is different from experimental neural-cell replacement strategies.
Human studies vary in injury level, completeness, chronicity, dose, route, and rehabilitation. Changes in motor or sensory scores must be interpreted carefully because spontaneous recovery can occur, especially early after injury.
Figure 4 placeholder — Spinal-cord injury
Multiple sclerosis
Multiple sclerosis is an immune-mediated disease of the central nervous system involving inflammation, demyelination, axonal damage, and variable neurodegeneration.
MSC research has explored immunomodulation and neuroprotective effects. Hematopoietic stem-cell transplantation is a separate treatment strategy intended to reset immune function in selected patients and should not be confused with MSC treatment.
Small MSC studies have examined safety, imaging, vision, and disability outcomes, but routine efficacy has not been established. Established disease-modifying therapies remain the appropriate clinical comparator.
Figure 5 placeholder — Multiple sclerosis
Parkinson’s disease
Parkinson’s disease is a progressive disorder involving loss of dopaminergic neurons and dysfunction of the nigrostriatal pathway as well as broader brain networks.
MSC and EV research has proposed trophic, anti-inflammatory, mitochondrial, and neuroprotective effects. These approaches are different from experimental programs designed to replace dopaminergic neurons using neural or pluripotent-cell-derived products.
Laboratory plausibility does not prove restoration of the damaged neural circuitry. Established medications and appropriately selected device-based therapies remain standard care.
Figure 6 placeholder — Parkinson’s disease
Alzheimer’s disease
Alzheimer’s disease is a progressive neurodegenerative disorder associated with amyloid, tau, synaptic dysfunction, neuroinflammation, neuronal loss, and failure of brain networks.
MSC and EV studies have proposed anti-inflammatory, trophic, and neuroprotective effects, but most evidence remains laboratory, animal, or early clinical research.
A change in a biomarker does not prove preservation of memory, thinking, daily function, or independence. Claims that a cell product regenerates the brain or reverses established dementia require direct clinical evidence.
Figure 7 placeholder — Alzheimer’s disease
ALS
ALS is a progressive disease affecting motor neurons. It can occur in different genetic and sporadic forms and can progress at very different rates.
Cell-based research has included MSC-derived products intended to change the environment around motor neurons rather than rebuild the entire motor system.
Studies have examined safety, biomarkers, and functional decline, but they do not support a class-wide claim that MSCs are effective for ALS. Multidisciplinary care and established disease-modifying treatments remain essential.
Figure 8 placeholder — ALS
Peripheral neuropathy
Peripheral neuropathy includes many different disorders of peripheral nerves. Causes can include diabetes, toxins, immune disease, inherited conditions, ischemia, and trauma.
A result in one type of neuropathy should not be assumed to apply to another. MSC and EV research has explored anti-inflammatory, vascular, trophic, and Schwann cell-supportive mechanisms, particularly in preclinical models.
Human evidence remains limited. Clinical care should first identify and treat the cause, manage pain and functional impairment, prevent complications, and use disease-specific therapy when available.
Figure 9 placeholder — Peripheral neuropathy
Products and routes are not interchangeable
Autologous and allogeneic MSCs, neural progenitor cells, pluripotent-cell-derived neural products, conditioned media, and EV preparations are different interventions.
Intravenous, intra-arterial, intrathecal administration, intracerebral administration, intraspinal delivery, and local injection also have different risks and biodistribution. Evidence from one product or route should not automatically be applied to another.
How neurologic studies can mislead
A functional outcome such as walking, speech, memory, independence, or disability is different from an imaging change or laboratory biomarker.
Acute neurologic injuries can improve through spontaneous recovery and rehabilitation. Progressive diseases can fluctuate or decline at different rates. Controlled studies are therefore essential before improvement is attributed to an investigational treatment.
Safety considerations
Potential risks depend on the product and route and can include infection, inflammatory or immune reactions, thrombo-inflammatory effects, seizures, and procedure-related neurologic injury.
Direct delivery into the brain, spinal canal, or spinal cord introduces additional procedural risks that are not present with less invasive administration.
Questions patients should ask
What exact neurologic diagnosis is being treated? What exact cell or EV product was studied? Was the evidence from humans with the same disease? What route and dose were used? Was there a control group? Were meaningful functional outcomes improved, or only biomarkers or imaging? How was spontaneous recovery handled? What established treatments are available? What are the procedure-specific risks?
Bottom line
Neurologic MSC and EV research is scientifically active but remains investigational.
The strongest interpretation keeps each disease separate, distinguishes MSC/EV signaling from true neural-cell replacement, and requires controlled human evidence showing durable, patient-important benefit before describing a treatment as effective or regenerative.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0803 Professional Edition and preserves all nine controlling neurologic Points.